Document Detail


Marrow matrix metalloproteinases (MMPs) and tissue inhibitors of MMP in acute leukaemia: potential role of MMP-9 as a surrogate marker to monitor leukaemic status in patients with acute myelogenous leukaemia.
MedLine Citation:
PMID:  12060118     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) were demonstrated to have important implications in the progression and invasiveness of many malignant disorders. In contrast, the biological significance of these molecules in human leukaemias is not clear. We determined the levels of MMP-2, MMP-9, TIMP-1 and TIMP-2 in the bone marrow of 37 patients with acute myelogenous leukaemia (AML) and 18 patients with acute lymphoblastic leukaemia (ALL) before chemotherapy. Nineteen bone marrow donors served as normal controls. After chemotherapy, sequential measurements were done during the course in 19 AML patients. The levels of TIMP-1 and TIMP-2 were significantly higher and MMP-9 levels were significantly lower in the AML and ALL patients than in the normal controls. MMP-2 levels were higher in ALL, but not AML patients, compared with controls. Moreover, the levels of marrow MMP-2 and MMP-9 did not parallel the numbers of leukaemic blasts in the peripheral blood. MMP-9 levels were significantly lower in the AML patients who achieved a complete remission (CR) than in those who did not (8.71 +/- 8.15 ng/ml vs 26.13 +/- 27.75 ng/ml, P < 0.05). The AML patients with lower MMP-9 levels (< or = 4.4 ng/ml) tended to have longer survival time than those with higher levels (> 12 months vs 4 months, P = 0.12). In addition, MMP-9 levels in the AML patients at CR rose to the same range as the controls, but dropped again at relapse, demonstrating a close relationship of marrow MMP-9 with disease status of AML. Therefore, we conclude that the level of marrow MMP-9 may be a useful surrogate marker for monitoring disease status in AML and propose it as a potential prognostic factor.
Authors:
Liang-In Lin; Dong-Tsamn Lin; Chi-Jen Chang; Cheng-Yeh Lee; Jih-Luh Tang; Hwei-Fang Tien
Related Documents :
19446878 - Mean cell volume can be an early predictor for the cytogenetic response of chronic myel...
7046928 - Amsa--a promising new agent in refractory acute leukemia.
10609798 - Clinical significance of the translocation (11;14)(q13;q32) in multiple myeloma.
7919428 - Prevalence of obesity in young adults with acute lymphoblastic leukemia.
16542168 - Flow-mediated dilatation and intima-media thickness in patients with lacunar infarctions.
12810428 - Correlations of y chromosome microchimerism with disease activity in patients with sle:...
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  British journal of haematology     Volume:  117     ISSN:  0007-1048     ISO Abbreviation:  Br. J. Haematol.     Publication Date:  2002 Jun 
Date Detail:
Created Date:  2002-06-12     Completed Date:  2002-09-10     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0372544     Medline TA:  Br J Haematol     Country:  England    
Other Details:
Languages:  eng     Pagination:  835-41     Citation Subset:  IM    
Affiliation:
School of Medical Technology, College of Medicine, University Hospital, National Taiwan University, #7 Chung-Shan S. Road, Taipei, Taiwan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Analysis of Variance
Biological Markers / analysis
Bone Marrow / chemistry*
Case-Control Studies
Humans
Leukemia, Myeloid, Acute / metabolism*
Matrix Metalloproteinase 2 / analysis
Matrix Metalloproteinase 9 / analysis*
Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism
Prognosis
Remission Induction
Statistics, Nonparametric
Survival Analysis
Tissue Inhibitor of Metalloproteinase-1 / analysis
Tissue Inhibitor of Metalloproteinase-2 / analysis
Tissue Inhibitor of Metalloproteinases / analysis*
Chemical
Reg. No./Substance:
0/Biological Markers; 0/Tissue Inhibitor of Metalloproteinase-1; 0/Tissue Inhibitor of Metalloproteinases; 127497-59-0/Tissue Inhibitor of Metalloproteinase-2; EC 3.4.24.24/Matrix Metalloproteinase 2; EC 3.4.24.35/Matrix Metalloproteinase 9

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory f...
Next Document:  Analysis of resveratrol-induced apoptosis in human B-cell chronic leukaemia.